0001593968-24-000878.txt : 20240620
0001593968-24-000878.hdr.sgml : 20240620
20240620163135
ACCESSION NUMBER: 0001593968-24-000878
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240618
FILED AS OF DATE: 20240620
DATE AS OF CHANGE: 20240620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MESSEMER DEBORAH M.
CENTRAL INDEX KEY: 0001754424
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38693
FILM NUMBER: 241056757
MAIL ADDRESS:
STREET 1: C/O ALLOGENE THERAPEUTICS, INC.
STREET 2: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allogene Therapeutics, Inc.
CENTRAL INDEX KEY: 0001737287
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 823562771
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 457-2700
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
primary_01.xml
PRIMARY DOCUMENT
X0508
4
2024-06-18
0001737287
Allogene Therapeutics, Inc.
ALLO
0001754424
MESSEMER DEBORAH M.
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
true
true
Common Stock
2024-06-18
4
S
false
18641
2.2793
D
166765
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/29/2023
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Exhibits: Power of Attorney
/s/Earl Douglas, Attorney-in-Fact
2024-06-20
EX-24
2
dmessemerpoa.txt
EX-24 DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes
and appoints each of Earl Douglas, Geoffrey Parker, Annie Yoshiyama, and
Lillian Smith of Allogene Therapeutics, Inc. (the Company), signing
individually, the undersigneds true and lawful attorney-in fact and agent
to:
(1) execute for and on behalf of the undersigned, an officer, director or
holder of 10% of more of a registered class of securities of the Company,
Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities
Exchange Act of 1934, as amended (the Exchange Act) and the rules
thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned
that may be necessary or desirable to complete and execute such Form 3, 4
or 5, complete and execute any amendment or amendments thereto, and timely
file such forms or amendments with the United States Securities and
Exchange Commission and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of
benefit, in the best interest of, or legally required by, the undersigned,
it being understood that the documents executed by such attorney-in-fact on
behalf of the undersigned pursuant to this Power of Attorney shall be in
such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-facts discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in- facts substitute or substitutes,
shall lawfully have done, do, or cause to be done by virtue of this power
of attorney and the rights and powers herein granted. The undersigned
acknowledges that each of the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, is not assuming, nor is
the Company assuming, any of the undersigneds responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
earliest to occur of (a) the undersigned is no longer required to file
Forms 3, 4 and 5 with respect to the undersigneds holdings of and
transactions in securities issued by the Company, (b) revocation by the
undersigned in a signed writing delivered to the foregoing attorney-in-fact
or (c) until such attorney-in-fact shall no longer be employed by the
Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 17 day of June 2024.
Deborah Messemer
Deborah Messemer (Jun 17, 2024 18:20 PDT)
(Signature)
Deborah Messemer
(Name: Printed or Typed)